+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Alzheimer's Disease Market and Forecast Analysis 2034

  • ID: 3797410
  • Drug Pipelines
  • 300 pages
  • Datamonitor Healthcare
1 of 2
Disease Overview
Alzheimer's disease is an irreversible, progressive, neurodegenerative, and fatal disease that slowly affects memory, cognition, and function. Alzheimer's disease is the most common cause of dementia among older people. Dementia is the loss of cognitive functioning – thinking, remembering, and reasoning – and behavioral abilities, to such an extent that it interferes with a person’s daily life and activities. Dementia ranges in severity from mild to the most severe stage, when the person must depend completely on others for basic activities of daily living.

Market Snapshot
  • Solanezumab’s failure will likely impede the uptake of future beta amyloid antibodies.
  • The author’s survey sheds light on the changing landscape of prescribing patterns in Alzheimer’s disease.
  • Alzheimer’s disease inflicts a significant burden in the US, Japan, and five major EU markets.
  • A number of commercially successful brands are now reaching the end of their lifecycle.
  • Solanezumab's suspension has not stifled ongoing development of other amyloid-targeting therapies.
Note: Product cover images may vary from those shown
2 of 2
FORECAST: ALZHEIMER’S DISEASE (Published on 21 June 2017)
Overview
Executive Summary
Market Overview And Trends
Market Definition And Methodology
Aducanumab
Aricept (Donepezil)
Crenezumab
Exelon/Exelon Patch (Rivastigmine)
Namenda/Xr (Memantine)
Razadyne (Galantamine)
Rvt-101
Primary Research Methodology

TREATMENT: ALZHEIMER'S DISEASE (Published on 21 June 2017)
Overview
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Country Treatment Trees
Current Treatment Options
Prescribing Trends
Unmet Needs In Alzheimer’S Disease

EPIDEMIOLOGY: ALZHEIMER’S DISEASE (Published on 25 February 2019)
Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Mild Cognitive Impairment

MARKETED DRUGS: ALZHEIMER'S DISEASE (Published on 21 June 2017)
Overview
Executive Summary
Product Overview
Product Profile: Aricept
Product Profile: Exelon/Exelon Patch
Product Profile: Namenda
Product Profile: Razadyne

PIPELINE: ALZHEIMER’S DISEASE (Published on 21 June 2017)
Overview
Executive Summary
Clinical Pipeline Overview
Clinical Trial Design
Recently Discontinued Drugs
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Lmtx
Product Profile (Late Stage): Rvt-101
Product Profile (Late Stage): Aducanumab
Product Profile (Late Stage): Azeliragon
Product Profile (Late Stage): Crenezumab
Product Profile (Late Stage): Gantenerumab
Product Profile (Late Stage): Verubecestat

LIST OF FIGURES
Figure 1: Alzheimer’s disease market sales value in the US, Japan, and five major EU markets, by country, 2015-24
Figure 2: Alzheimer’s disease drug class sales in the US, Japan, and five major EU markets, 2015-24
Figure 3: Sales of cholinesterase inhibitors in the US, Japan, and five major EU markets, by country, 2015-24
Figure 4: Sales of NMDA receptor antagonists in the US, Japan, and five major EU markets, by country, 2015-24
Figure 5: Alzheimer’s disease market sales value by disease severity in the US, Japan, and five major EU markets, 2015-24
Figure 6: Patient-based forecast methodology for Alzheimer’s disease
Figure 7: Price sources and calculations, by country
Figure 8: Aducanumab sales for Alzheimer’s disease across the US, Japan, and five major EU markets, by country, 2015-24
Figure 9: Aricept sales for Alzheimer’s disease across the US, Japan, and five major EU markets, by country, 2015-24
Figure 10: Crenezumab sales for Alzheimer’s disease across the US, Japan, and five major EU markets, by country, 2015-24
Figure 11: Exelon/Exelon Patch sales for Alzheimer’s disease across the US, Japan, and five major EU markets, by country, 2015-24
Figure 12: Namenda/XR sales for Alzheimer’s disease across the US, Japan, and five major EU markets, by country, 2015-24
Figure 13: Razadyne sales for Alzheimer’s disease across the US, Japan, and five major EU markets, by country, 2015-24
Figure 14: RVT-101 sales for Alzheimer’s disease across the US, Japan, and five major EU markets, by country, 2015-24
Figure 15: Hypothetical model of dynamic biomarkers taking place with disease severity
Figure 16: Neurologist-reported Alzheimer’s disease diagnosis rates, by country, 2015
Figure 17: Hypothesized beta-amyloid pathway in Alzheimer’s disease and therapeutic strategies
Figure 18: Hypothesized tau pathway in Alzheimer’s disease and therapeutic strategies
Figure 19: The dynamics in biomarkers of the Alzheimer’s disease pathological cascade
Figure 20: Estimated prevalent and diagnosed prodromal and Alzheimer’s disease patient populations in the US, Japan, and five major EU markets, by country, 2015
Figure 21: Diagnosed Alzheimer’s disease patients in the US, Japan, and five major EU markets, by disease severity and country, 2015
Figure 22: Estimated prevalent, diagnosed, and drug-treated prodromal and Alzheimer’s disease patients in the US, Japan, and five major EU markets, by country, 2015
Figure 23: Proportion of drug-treated patients in the US, Japan, and five major EU markets, by disease severity and country (%), 2015
Figure 24: Pharmacological treatment rates for diagnosed Alzheimer’s patients in the US, Japan, and five major EU markets, by disease severity and country (%), 2015
Figure 25: Treatment choices for patients diagnosed with prodromal Alzheimer’s disease in the US, Japan, and five major EU markets, by country (%), 2015
Figure 26: Treatment choices for patients diagnosed with mild Alzheimer’s disease in the US, Japan, and five major EU markets, by country (%), 2015
Figure 27: Treatment choices for patients diagnosed with moderate Alzheimer’s disease in the US, Japan, and five major EU markets, by country (%), 2015
Figure 28: Treatment choices for patients diagnosed with severe Alzheimer’s disease in the US, Japan, and five major EU markets, by country (%), 2015
Figure 29: Prescription trends in patients diagnosed with prodromal Alzheimer’s disease in the US, Japan, and five major EU markets, by country (%), 2015
Figure 30: Prescription trends in patients diagnosed with mild Alzheimer’s disease in the US, Japan, and five major EU markets, by country (%), 2015
Figure 31: Prescription trends in patients diagnosed with moderate Alzheimer’s disease in the US, Japan, and five major EU markets, by country (%), 2015
Figure 32: Prescription trends in patients diagnosed with severe Alzheimer’s disease in the US, Japan, and five major EU markets, by country (%), 2015
Figure 33: Preference for rivastigmine patch over oral formulation for all severities of Alzheimer’s disease, by country (%), 2015
Figure 34: Proportion of Alzheimer’s disease patients receiving either memantine monotherapy or in combination, by country (%), 2015
Figure 35: Compliance rates to oral versus transdermal patch formulations in patients with Alzheimer’s disease, by country (%), 2015
Figure 36: Key unmet needs for Alzheimer’s disease, 2015
Figure 37: Impact of symptomatic versus disease-modifying drugs on quality of life/life expectancy over the course of the disease
Figure 38: NHS’s recommended referral pathway for patients presenting to primary care with dementia
Figure 39: Trends in total prevalent cases of Alzheimer’s disease in the US, Japan, and five major EU markets, by country, 2018–38
Figure 40: Aricept for Alzheimer's disease – SWOT analysis
Figure 41: The authors drug assessment summary of Aricept in Alzheimer’s disease
Figure 42: The authors drug assessment summary of Aricept in Alzheimer’s disease
Figure 43: Exelon/Exelon Patch for Alzheimer's disease – SWOT analysis
Figure 44: The authors drug assessment summary of Exelon in Alzheimer’s disease
Figure 45: The authors drug assessment summary of Exelon in Alzheimer’s disease
Figure 46: Namenda for Alzheimer's disease – SWOT analysis
Figure 47: The authors drug assessment summary of Namenda in Alzheimer’s disease
Figure 48: The authors drug assessment summary of Namenda in Alzheimer’s disease
Figure 49: Razadyne for Alzheimer's disease – SWOT analysis
Figure 50: The authors drug assessment summary of Razadyne in Alzheimer’s disease
Figure 51: The authors drug assessment summary of Razadyne in Alzheimer’s disease
Figure 52: Clinical trial designs proposed to determine disease modification
Figure 53: LMTX for Alzheimer’s disease – SWOT analysis
Figure 54: The authors drug assessment summary of LMTX in Alzheimer’s disease
Figure 55: The authors drug assessment summary of LMTX in Alzheimer’s disease
Figure 56: RVT-101 for Alzheimer’s disease – SWOT analysis
Figure 57: The authors drug assessment summary of RVT-101 in Alzheimer’s disease
Figure 58: The authors drug assessment summary of RVT-101 in Alzheimer’s disease
Figure 59: Aducanumab for Alzheimer’s disease – SWOT analysis
Figure 60: The authors drug assessment summary of aducanumab in Alzheimer’s disease
Figure 61: The authors drug assessment summary of aducanumab in Alzheimer’s disease
Figure 62: Azeliragon for Alzheimer’s disease – SWOT analysis
Figure 63: The authors drug assessment summary of azeliragon in Alzheimer’s disease
Figure 64: The authors drug assessment summary of azeliragon in Alzheimer’s disease
Figure 65: Crenezumab for Alzheimer’s disease – SWOT analysis
Figure 66: The authors drug assessment summary of crenezumab in Alzheimer’s disease
Figure 67: The authors drug assessment summary of crenezumab in Alzheimer’s disease
Figure 68: Gantenerumab for Alzheimer’s disease – SWOT analysis
Figure 69: The authors drug assessment summary of gantenerumab in Alzheimer’s disease
Figure 70: The authors drug assessment summary of gantenerumab in Alzheimer’s disease
Figure 71: Verubecestat for Alzheimer’s disease – SWOT analysis
Figure 72: The authors drug assessment summary of verubecestat in Alzheimer’s disease
Figure 73: The authors drug assessment summary of verubecestat in Alzheimer’s disease
Figure 74: Hypothetical model of dynamic biomarkers taking place with disease severity

LIST OF TABLES
Table 1: Alzheimer’s disease market sales value in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 2: Alzheimer’s disease drug class sales in the US, Japan, and five major EU markets ($m), 2015-24
Table 3: Sales of cholinesterase inhibitors in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 4: Sales of NMDA receptor antagonists in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 5: Alzheimer’s disease market sales value by disease severity in the US, Japan, and five major EU markets ($m), 2015–24
Table 6: Summary of drug classes and molecules in The authors Alzheimer’s disease patient-based forecast
Table 7: Exchange rates used for calculating prices
Table 8: Estimated patent expiry/loss of exclusivity dates for key marketed brands in Alzheimer’s disease in the US, Japan, and five major EU markets, by country
Table 9: Estimated launch dates of key late-stage pipeline products in Alzheimer’s disease, by country, 2015-24
Table 10: Aducanumab’s dose and price assumptions, by country, 2016
Table 11: Aducanumab sales for Alzheimer’s disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 12: Aricept sales for Alzheimer’s disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 13: Crenezumab’s dose and price assumptions, by country, 2016
Table 14: Crenezumab sales for Alzheimer’s disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 15: Exelon/Exelon Patch sales for Alzheimer’s disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 16: Namenda/XR sales for Alzheimer’s disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 17: Razadyne sales for Alzheimer’s disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 18: RVT-101 sales for Alzheimer’s disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 19: Neurologists surveyed for the Alzheimer’s disease primary research study, 2015
Table 20: Pipeline products discussed in the key opinion leader research interviews
Table 21: Neurologists surveyed for the Alzheimer’s disease primary research study, 2015
Table 22: Common clinical features of Alzheimer’s disease
Table 23: Dementia caregiver tasks
Table 24: Estimated number of diagnosed Alzheimer’s disease patients in the US, Japan, and five major EU markets, by disease severity and country, 2015
Table 25: Estimated number of drug-treated Alzheimer’s disease patients in the US, Japan, and five major EU markets, by disease severity and country, 2015
Table 26: Leading therapies for Alzheimer’s disease
Table 27: Commonly used guidelines for the treatment of Alzheimer’s disease
Table 28: Pharmacological treatment rates for diagnosed Alzheimer’s patients in the US, Japan, and five major EU markets, by disease severity and country (%), 2015
Table 29: Prescription trends in patients diagnosed with prodromal Alzheimer’s disease in the US, Japan, and five major EU markets, by country (%), 2015
Table 30: Prescription trends in patients diagnosed with mild Alzheimer’s disease in the US, Japan, and five major EU markets, by country (%), 2015
Table 31: Prescription trends in patients diagnosed with moderate Alzheimer’s disease in the US, Japan, and five major EU markets, by country (%), 2015
Table 32: Prescription trends in patients diagnosed with severe Alzheimer’s disease in the US, Japan, and five major EU markets, by country (%), 2015
Table 33: Summary of the global and cognitive response of Alzheimer’s disease patients to acetylcholinesterase inhibitor treatment
Table 34: Aricept’s side-effect profile
Table 35: Sources used for the epidemiological analysis of Alzheimer’s disease in the US, Japan, and EU markets, by country
Table 36: Total prevalent cases of Alzheimer’s disease in the US, Japan, and five major EU markets, by country, 2018–38
Table 37: Total prevalent cases of mild cognitive impairment due to Alzheimer’s disease in the US, Japan, and five major EU markets, by country, 2018–38
Table 38: Key marketed drugs for Alzheimer’s disease
Table 39: Aricept drug profile
Table 40: Aricept pivotal trial data in Alzheimer’s disease
Table 41: Exelon/Exelon Patch drug profile
Table 42: Exelon pivotal trial data in Alzheimer’s disease
Table 43: Exelon Patch pivotal trial data in Alzheimer’s disease
Table 44: Namenda drug profile
Table 45: Namenda pivotal trial data in Alzheimer’s disease
Table 46: Razadyne drug profile
Table 47: Razadyne pivotal trial data in Alzheimer’s disease
Table 48: Phase III pipeline products in development for Alzheimer’s disease
Table 49: FDA and EMA recommendations for clinical trial endpoints in Alzheimer’s disease
Table 50: FDA and EMA recommendations on clinical trial design to demonstrate disease-modifying effects
Table 51: Encenicline drug profile
Table 52: Encenicline late-phase trials in Alzheimer’s disease
Table 53: Idalopirdine drug profile
Table 54: Idalopirdine late-phase trials in Alzheimer’s disease
Table 55: Solanezumab drug profile
Table 56: Solanezumab late-phase trials in Alzheimer’s disease
Table 57: LMTX drug profile
Table 58: LMTX Phase III data in Alzheimer’s disease
Table 59: LMTX Phase III trials in Alzheimer’s disease
Table 60: RVT-101 drug profile
Table 61: RVT-101 Phase II data in Alzheimer’s disease
Table 62: RVT-101 Phase III trials in Alzheimer’s disease
Table 63: Aducanumab drug profile
Table 64: Aducanumab Phase Ib data in Alzheimer’s disease
Table 65: Aducanumab Phase III trials in Alzheimer’s disease
Table 66: Azeliragon drug profile
Table 67: Azeliragon Phase IIb data in Alzheimer’s disease
Table 68: Azeliragon Phase III trials in Alzheimer’s disease
Table 69: Crenezumab drug profile
Table 70: Crenezumab Phase II data in Alzheimer’s disease
Table 71: Crenezumab Phase III trials in Alzheimer’s disease
Table 72: Gantenerumab drug profile
Table 73: Gantenerumab Phase III data in Alzheimer’s disease
Table 74: Gantenerumab Phase III trials in Alzheimer’s disease
Table 75: Verubecestat drug profile
Table 76: Verubecestat Phase Ib data in Alzheimer’s disease
Table 77: Verubecestat Phase II/III trials in Alzheimer’s disease
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Order Online - visit: https://www.researchandmarkets.com/reports/3797410
Adroll
adroll